title: Nonincretin drugs in later-stage development.
authors.forename: Marj P
authors.initials: MP
authors.lastname: Zimmerman
authors.forename: Stanton R
authors.initials: SR
authors.lastname: Mehr
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D048588:Benzoxazines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D004338:Drug Combinations; D004348:Drug Labeling; D015507:Drugs, Investigational; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy* / Q000453:epidemiology; D010645:Phentermine / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D019440:Anti-Obesity Agents; D001552:Benzazepines; D048588:Benzoxazines; D004338:Drug Combinations; D015507:Drugs, Investigational; C576188:Qsymia; C000591595:bupropion hydrochloride, naltrexone hydrochoride drug combination; D016642:Bupropion; D005632:Fructose; D009271:Naltrexone; C506658:lorcaserin; D010645:Phentermine; C520092:cetilistat